

BridgeBio Pharma (USA): Merger with Eidos Therapeutics (USA) Changes in FTSE Indexes

22 January 2021

Subject to the completion of the merger between BridgeBio Pharma (USA, constituent) and Eidos Therapeutics (USA, non-constituent), please see details of affected indexes and effective dates below:

Index	Effective From Start of Trading
FTSE Global Small Cap Index	27 January 2021

*In the absence of an active market, Eidos Therapeutics will be removed at the default merger terms of 1.85 shares of BridgeBio Pharma for each share of Eidos Therapeutics held.

**Based on the default merger terms of 1.85 shares of BridgeBio Pharma per share of Eidos Therapeutics held.

For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:

Australia	+1800 653 680
Hong Kong	+852 2164 3333
Japan	+81 3 4563 6346
London	+44 (0) 20 7866 1810
New York	+1866 551 0617

Alternatively please visit our website at www.ftserussell.com

[Terms of Use](#) | Copyright © 2021 FTSE Russell